{"id":"background-arvs","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Lipodystrophy"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Lactic acidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Background ARVs refer to the foundational antiretroviral therapy regimens used in HIV treatment, typically consisting of combinations of nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), or integrase strand transfer inhibitors (INSTIs). These drugs work synergistically to block different stages of the HIV replication cycle, preventing viral multiplication and allowing immune system recovery.","oneSentence":"Background ARVs are antiretroviral drugs that suppress HIV replication through various mechanisms including reverse transcriptase inhibition, protease inhibition, and integrase inhibition.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:28:10.935Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (treatment and suppression)"}]},"trialDetails":[{"nctId":"NCT02494986","phase":"PHASE2","title":"A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Sciences Ireland UC","startDate":"2015-07-06","conditions":"Human Immunodeficiency Virus Type 1","enrollment":48},{"nctId":"NCT04012931","phase":"PHASE2","title":"A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-07-18","conditions":"HIV","enrollment":26},{"nctId":"NCT00751530","phase":"","title":"BRAVO: Background Regimen of Raltegravir on Virologic Outcome","status":"COMPLETED","sponsor":"Community Research Initiative of New England","startDate":"2008-03-01","conditions":"HIV Infections","enrollment":442},{"nctId":"NCT00089492","phase":"PHASE2","title":"A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-07","conditions":"HIV Infections","enrollment":64},{"nctId":"NCT00326963","phase":"PHASE4","title":"BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-03","conditions":"HIV Infections","enrollment":142}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":458,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Background ARVs","genericName":"Background ARVs","companyName":"Hoffmann-La Roche","companyId":"hoffmann-la-roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Background ARVs are antiretroviral drugs that suppress HIV replication through various mechanisms including reverse transcriptase inhibition, protease inhibition, and integrase inhibition. Used for HIV-1 infection (treatment and suppression).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}